Harmony Biosciences: A Downside‑Heavy Play Amid Rising Volatility

Five risk flags and a deep drawdown history suggest the stock may absorb more losses than gains in the coming months

HRMY Harmony Biosciences Holdings, Inc.

In this report

01

Returns Overview

Period returns, alpha, cumulative performance, distributions

P. 2-3

→

02

Volatility Analysis

Annualized volatility, downside deviation, drawdowns

P. 4-5

→

03

Beta & Correlation

Trailing, upside, downside beta, systematic risk

P. 6-7

→

04

Risk-Adjusted Returns

Sharpe, Sortino, Calmar, Information, Treynor

P. 8-9

→

05

Market Regime Analysis

Bull/bear behavior, capture ratios

P. 10-11

→

06

Investment Highlights & Risk Summary

Executive summary, risk flags, rankings

P. 12-13

→

Returns Overview

Harmony Biosciences Holdings, Inc. (HRMY) — Return Performance

Harmony Biosciences Holdings, Inc. (HRMY) delivered modest absolute returns over the past five years, with a 5‑year cumulative gain of 14.06% versus a sector underperformance of -57.75%. The stock’s performance has been highly variable: it posted strong short‑term gains in the 3‑month window (+14.96%) while generating negative alpha against its XLV benchmark (-21.81%). Over longer horizons, HRMY lagged the sector consistently, posting negative alpha in every horizon beyond one month, most notably a -74.41% alpha over three years.

Period Returns vs S&P 500 & XLV

Monthly Returns Heatmap

HRMY

HRMY produced positive absolute returns only in the 1‑month (+1.93%) and 3‑month (+14.96%) periods, but both were offset by substantial sector outperformance gaps, especially a -21.81% alpha over six months. The divergence between short‑term upside and long‑term underperformance suggests that recent catalysts may be temporary, while structural challenges have weighed on the stock’s ability to generate sustained alpha against the healthcare sector.

Returns Overview

Harmony Biosciences Holdings, Inc. (HRMY) — Return Charts

Volatility Analysis

Harmony Biosciences Holdings, Inc. (HRMY) — Volatility Profile

Harmony Biosciences Holdings (HRMY) exhibits markedly higher price variability than the broader market, with an annualized volatility of 52.39% compared to the S&P 500's 17.78%, indicating more than three times the typical market swing. The stock’s downside risk is pronounced: a downside deviation of 41.03% and a maximum historical drawdown of -68.48% over a ten‑month period underscore substantial vulnerability during adverse market phases. Recent short‑term volatility remains elevated, as the 60‑day vol of 35.32% exceeds the longer‑term 252‑day average of 41.6%, suggesting that recent price swings are still above the historical norm despite being slightly lower than the one‑year figure.

Volatility Metrics

HRMY

The company’s volatility profile is considerably more aggressive than the S&P 500 benchmark, reflecting its biopharma development stage and limited operating history. Downside risk metrics—downside deviation of 41.03% and a max drawdown of -68.48% lasting roughly eleven months—highlight that investors have faced steep losses with no recovery to prior peaks yet. While the 60‑day volatility (35.32%) is below the 252‑day level (41.6%), it remains well above market averages, indicating persistent short‑term price turbulence.

HRMY’s annualized volatility of 52.39% is more than three times that of the S&P 500.
Downside deviation stands at 41.03%, signaling high sensitivity to negative market moves.
The maximum drawdown of -68.48% persisted for nearly a year without any recovery.
Short‑term (60‑day) volatility is lower than the one‑year average but still far exceeds broader market levels.

Positive Characteristics
Recent 60‑day volatility has eased relative to the 252‑day average, suggesting a modest short‑term calming of price swings.
The company’s risk metrics, while elevated, are transparent and quantifiable for risk‑adjusted portfolio construction.

Volatility Analysis

Harmony Biosciences Holdings, Inc. (HRMY) — Volatility & Drawdown Charts

Beta & Correlation

Harmony Biosciences Holdings, Inc. (HRMY) — Beta Profile

Harmony Biosciences Holdings (HRMY) exhibits a trailing beta of 0.837 versus the S&P 500, placing it in the defensive to market‑like range (0.8‑1.2). This indicates that the stock moves roughly 16% less than the broad market on average, providing modest downside protection while still participating in upside trends. However, the low R-squared of 7.2% and correlation of 0.269 reveal that only a small fraction of HRMY’s price movements are explained by overall market dynamics, suggesting that most of its risk is idiosyncratic and not captured by traditional equity market factors. The asymmetric beta profile—upside beta of 0.788 versus downside beta of 0.609—shows that the stock reacts more strongly to positive market moves than to negative ones, a characteristic that can be advantageous for investors seeking upside capture while limiting loss exposure. When compared with its sector benchmark (Healthcare XLV), HRMY’s sector beta of 0.933 and sector correlation of 0.263 are slightly higher than the market beta, implying that sector forces account for a modest portion of its risk but still less than half of total variance. The systematic component of 7.2% versus an idiosyncratic component of 92.8% underscores that HRMY’s price action is driven primarily by company‑specific factors rather than broad market or sector trends.

Beta & Correlation Metrics

HRMY

The trailing beta of 0.837 signals a defensive tilt, meaning the stock tends to underperform in strong bull markets but also cushions losses during downturns relative to the S&P 500. The upside‑downside beta split (0.788 vs 0.609) highlights an asymmetric risk profile: HRMY captures roughly 79% of positive market moves while only reflecting about 61% of negative moves, offering a modest bias toward upside participation. With an R-squared of just 7.2%, diversification benefits are strong because most price variation stems from idiosyncratic sources rather than market co‑movement.

Trailing beta of 0.837 places HRMY in a defensive to market‑like range, indicating lower sensitivity to overall market swings.
Upside beta (0.788) exceeds downside beta (0.609), suggesting the stock gains more from market rallies than it loses from declines.
R-squared of 7.2% means only a small share of HRMY’s returns are driven by systematic market factors, enhancing diversification potential.
Systematic risk accounts for 7.2% of total variance while idiosyncratic risk dominates at 92.8%, emphasizing company‑specific drivers.
Sector beta (0.933) is slightly higher than market beta, indicating that healthcare sector movements contribute marginally more to HRMY’s volatility than the broader market.

Positive Characteristics
Low overall market correlation (0.269) reduces exposure to broad equity downturns.
High idiosyncratic risk share (92.8%) offers opportunities for active stock‑specific strategies.
Asymmetric upside beta provides better participation in bullish periods while limiting downside sensitivity.

Beta & Correlation

Harmony Biosciences Holdings, Inc. (HRMY) — Rolling Beta

Positive Notes

Low overall market correlation (0.269) reduces exposure to broad equity downturns.

High idiosyncratic risk share (92.8%) offers opportunities for active stock‑specific strategies.

Asymmetric upside beta provides better participation in bullish periods while limiting downside sensitivity.

Risk-Adjusted Returns

Harmony Biosciences Holdings, Inc. (HRMY) — Risk-Adjusted Performance

Harmony Biosciences Holdings (HRMY) delivers modest risk-adjusted returns in the current market environment. With a Sharpe ratio of 0.154, the stock generates a small excess return over the risk‑free rate per unit of total volatility, well below the benchmark threshold of 1.0 that denotes strong performance. The Sortino ratio of 0.196 exceeds the Sharpe figure, indicating that downside volatility is lower than overall volatility and that the equity’s returns are less penalized by adverse price movements.

Risk-free rate: 3.63% (Fed Funds Rate)

Risk-Adjusted Metrics

HRMY

The Calmar ratio of 0.171 reflects a relatively weak return‑to‑drawdown profile; the company’s historical peak‑to‑trough loss is sizable compared with its annualized return, suggesting that investors have endured pronounced drawdowns. The Information Ratio of -0.065 signals negative alpha relative to a benchmark, implying that active management has not added value and may have underperformed the reference index. Meanwhile, the Treynor ratio of 9.616 appears high because it divides the modest excess return by a low beta, but this figure alone can be misleading without strong Sharpe or Information metrics to corroborate systematic risk compensation.

Sharpe (0.154) and Sortino (0.196) are both well below 1.0, indicating limited excess return for the amount of total and downside risk taken.
The higher Sortino relative to Sharpe suggests that downside volatility is less pronounced than overall volatility.
Calmar ratio (0.171) points to a severe max drawdown relative to annualized returns, highlighting potential capital erosion during market downturns.
Negative Information Ratio (-0.065) denotes underperformance against the benchmark and a lack of consistent alpha generation.

Positive Characteristics
Sortino ratio exceeds Sharpe, reflecting a comparatively favorable downside risk profile.
Treynor ratio is elevated, indicating that per unit of systematic risk the stock has delivered modest excess return, though this must be weighed against weak overall risk‑adjusted metrics.

Risk-Adjusted Returns

Harmony Biosciences Holdings, Inc. (HRMY) — Rolling Sharpe & Sortino

Positive Notes

Sortino ratio exceeds Sharpe, reflecting a comparatively favorable downside risk profile.

Treynor ratio is elevated, indicating that per unit of systematic risk the stock has delivered modest excess return, though this must be weighed against weak overall risk‑adjusted metrics.

Market Regime Analysis

Harmony Biosciences Holdings, Inc. (HRMY) — Regime Behavior

Harmony Biosciences Holdings (HRMY) exhibits a pronounced sensitivity to market volatility within bullish environments. In the Bull-HighVol regime—characterized by an upward‑trending S&P 500 combined with elevated realized volatility—the stock delivers an average monthly gain of 4.9%, markedly outperforming its modest -0.84% return in the calmer Bull-LowVol setting. Conversely, during bearish periods the company’s performance deteriorates sharply, posting a -9.6% average loss in Bear‑LowVol and a still sizable -2.62% decline in Bear‑HighVol, though the latter is less severe due to heightened volatility providing some downside cushioning. The upside capture of 100.3% indicates that HRMY tracks the market’s gains almost one‑for‑one during up markets, while its downside capture of 137.4% reveals a tendency to lose more than the broader market in down markets, resulting in a net capture ratio of 0.73.

Current Market Regime: Bull-HighVol

Bull-LowVol = calm uptrend • Bull-HighVol = volatile uptrend • Bear-LowVol = orderly decline • Bear-HighVol = crisis

Regime Returns & Capture Ratios

HRMY

In bullish regimes, HRMY thrives when volatility is high, generating near‑5% average monthly returns, but its performance stalls in low‑vol environments, suggesting the stock benefits from price swings that amplify its growth catalysts. In bearish regimes, the firm lacks defensive characteristics; it suffers a steep -9.6% loss during orderly declines and only moderates losses to -2.62% when volatility spikes, indicating limited downside protection. The current Bull-HighVol regime aligns with HRMY’s strongest historical return profile, implying that short‑term upside potential remains robust provided market turbulence persists.

Market Regime Analysis

Harmony Biosciences Holdings, Inc. (HRMY) — Regime & Capture Charts

Regime Timeline

HRMY’s average return jumps from -0.84% in Bull-LowVol to +4.9% in Bull-HighVol, highlighting volatility as a key driver of performance.
Downside capture of 137.4% signals that the stock loses substantially more than the market during declines, making it non‑defensive.
The net capture ratio of 0.73 falls below the ideal threshold of 1.0, reflecting an asymmetry where upside gains are outweighed by downside losses.
In Bear-HighVol periods, HRMY’s loss narrows to -2.62% versus -9.6% in Bear-LowVol, suggesting some resilience when market stress intensifies.

Positive Characteristics
Strong upside capture (100.3%) indicates the stock participates fully in bullish moves.
Reduced losses during volatile bear markets (-2.62% vs -9.6%) show a modest defensive tilt under heightened volatility.

Investment Highlights & Risk Summary

Harmony Biosciences Holdings, Inc. (HRMY) — Summary & Implications

Harmony Biosciences Holdings (HRMY) delivered a modest 1.9% total return over the past year, but its performance lagged both the S&P 500 and the healthcare sector, generating an alpha of -17.1% versus the market and -12.6% versus XLV. The stock exhibits pronounced risk characteristics: annualized volatility of 52.39% far exceeds the S&P 500's typical 15-20%, while a maximum drawdown of -68.48% underscores its susceptibility to deep capital losses. Risk-adjusted metrics are weak, with a Sharpe ratio of only 0.154 and a Sortino of 0.196, indicating limited excess return per unit of total or downside risk. Capture ratios reveal an unfavorable profile—upside capture is roughly neutral at 100.3% but downside capture spikes to 137.4%, meaning the stock magnifies market declines more than it participates in gains. Investors should weigh these dynamics against the company's growth narrative and pipeline potential, which are not reflected in the short‑term quantitative metrics. The beta of 0.837 suggests lower systematic risk relative to the market, yet the high downside capture implies that during bearish regimes HRMY can underperform more sharply than its beta would suggest. For a portfolio seeking exposure to biotech innovation, HRMY may provide sector-specific upside, but the historical drawdown and volatility demand a cautious position size and robust risk controls. Over the next 6‑18 months, the key determinants of performance will be clinical trial outcomes, regulatory milestones, and broader market sentiment toward high‑volatility biotech stocks. If the company achieves positive data releases, the upside capture could translate into meaningful gains; however, any setbacks are likely to exacerbate the already elevated downside risk. Consequently, HRMY is best suited for investors with a high tolerance for volatility who can absorb potential large losses while targeting long‑term therapeutic breakthroughs.

Summary Dashboard

Investment Highlights

Beta of 0.837 indicates lower sensitivity to broad market moves, potentially moderating systematic risk in diversified portfolios.
Upside capture of 100.3% shows the stock can keep pace with market rallies when sentiment turns positive.
The healthcare sector beta of 0.933 suggests HRMY moves roughly in line with its sector, providing exposure to biotech trends without excessive deviation.

Risk-Return Rankings

HRMY HIGH

High volatility and deep drawdown dominate a modest return profile, resulting in an elevated risk-return balance.

Strength: Low overall beta (0.837) reduces systematic exposure relative to the market.

Concern: Maximum drawdown of -68.48% and downside capture of 137.4% signal severe loss potential during market declines.

Key Takeaways

HRMY underperformed both the S&P 500 (-17.1% alpha) and its healthcare sector peers (-12.6% sector alpha) over the past year.
Volatility of 52.39% and a Sharpe ratio of 0.154 indicate that risk taken is not compensated by commensurate returns.
Downside capture exceeding 130% means the stock amplifies market losses, posing asymmetric downside risk.
Low beta offers some protection against broad market swings but does not offset the high idiosyncratic volatility.

PORTFOLIO IMPLICATIONS

Given its high volatility and deep drawdown history, HRMY is appropriate for a small allocation within a broader, diversified portfolio that can tolerate significant short‑term fluctuations. Its low beta may complement higher‑beta holdings by dampening overall systematic risk, but the pronounced downside capture necessitates strict position sizing and possibly hedging strategies during bearish market phases. Investors seeking biotech exposure should consider pairing HRMY with more stable healthcare instruments to balance sector upside potential against its asymmetric risk profile.

HRMY

Related Reports

Visit finexus.net/reports for more reports

Report written 2026-06-07 • Finexus

Disclaimer

This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.

The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.

Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.